

Complement activation as a therapeutic target and clinical biomarker for Parkinson's disease

<https://neurodegenerationresearch.eu/survey/complement-activation-as-a-therapeutic-target-and-clinical-biomarker-for-parkinsons-disease/>

Principal Investigators

A/Pr Trent Woodruff

Institution

University of Queensland

Contact information of lead PI

Country

Australia

Title of project or programme

Complement activation as a therapeutic target and clinical biomarker for Parkinson's disease

Source of funding information

National Health and Medical Research Council

Total sum awarded (Euro)

€ 332,144

Start date of award

01/01/2015

Total duration of award in years

3

Keywords

Research Abstract

Parkinson's disease is the second most common neurological disease in Australia, yet there is no treatment to slow disease progression. Our study is investigating inflammation within the brain as a major contributing factor in Parkinson's disease. We will examine this inflammatory pathway in human patients suffering from Parkinson's, and will test a novel anti-inflammatory drug in animal models of Parkinson's disease, in order to identify a novel treatment to reduce disease pathology.

Further information available at:

Types:

Investments < €500k

Member States:

Australia

Diseases:

N/A

Years:

2016

Database Categories:

N/A

Database Tags:

N/A